Drugs / Batroxobin
Batroxobin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07352358 | Jan 2026 → Jul 2028 expected | cerebral sinovenous thrombosis | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 4 | NCT04269954 | Mar 2020 → Mar 2021 | cerebral sinovenous thrombosis | Capital Medical University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | batroxobin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07352358 ↗ |
| Known as | Batroxobina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108904 ↗ |
| Known as | Batroxobine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108904 ↗ |
| Known as | Defibrase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108904 ↗ |
| Route | Intravenous | “Batroxobin 5 BU intravenous infusion” PMID 30062617 ↗ Oct 2018 |